<DOC>
	<DOCNO>NCT00003900</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine irinotecan docetaxel treat patient recurrent metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>Irinotecan With Docetaxel Treating Patients With Recurrent Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate previously treat patient recurrent non-small cell lung cancer treatment irinotecan docetaxel . II . Determine toxicity regimen patient . III . Determine overall survival patient population . OUTLINE : Patients receive irinotecan IV 90 minute immediately follow docetaxel IV 60 minute day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 5 year death .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Reconfirmation NSCLC require complete response great 1 year Measurable evaluable disease Tumor shrinkage stability least 4 week initial chemotherapy CNS metastases allow , symptom control great 8 week surgery radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : 01 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal AST great 2 time upper limit normal ( ULN ) Renal : Creatinine great 2.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease Other : No active infection At least 5 year since prior malignancy except curatively treat basal squamous cell skin cancer , carcinoma situ , cancers No grade 2 bad peripheral neuropathy No uncontrolled diabetes mellitus No serious underlie disease Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No great 1 prior NSCLC chemotherapy regimen , exclude low dose cisplatin radiosensitizer No prior irinotecan docetaxel At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy No prior radiotherapy great 25 % bone marrow Surgery : See Disease Characteristics Other : No concurrent phenytoin , phenobarbital , anticonvulsant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>